Nasdaq:US$18.25 (+1.31) | HKEX:HK$29.30 (+0.95) | AIM:£2.96 (+0.06)
Search
Scientific Publications

These scientific presentations/publications/posters are provided for scientific exchange and informational purposes only and may contain discussion on products that may be considered investigational in certain markets/countries. The information contained in each publication is accurate only as of the date it was originally issued and is not controlled by HUTCHMED. HUTCHMED assumes no responsibility for the information or statements in such publications and disavows any obligation to update the information contained in such publications after the date of their issuance.

1
2
found Documents: 87
Scientific Publications | 5 Apr 2023

THE LANCET Haematology: Sovleplenib for primary immune thrombocytopenia patients in China
Sovleplenib (HMPL-523), a novel Syk inhibitor, for patients with primary immune thrombocytopenia in China: a randomised, double-blind, placebo-controlled, phase 1b/2 study Xiaofan Liu, Hu Zhou, Yu Hu, Jie Yin, Junmin Li, Wenming Chen, Ruibin Huang
Read More
Scientific Publications | 17 Mar 2023

JSMO2023: Fruquintinib in Japanese patients with refractory metastatic CRC
The outcome for patients in Japan from the FRESCO-2 multi-regional clinical trial of fruquintinib, an oral inhibitor of VEGFR-1, -2 and -3, are being presented at the 2023 Japanese Society of Medical Oncology Annual Meeting, taking place March 16-18
Read More
Scientific Publications | 12 Sep 2022

ESMO2022: FRESCO-2: A global phase 3 multiregional clinical trial evaluating the efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer
Title: FRESCO-2: A global Phase 3 multi-regional clinical trial (MRCT) evaluating the efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer Presenter: Arvind Dasari, MD, MS, Associate Professor, Dep
Read More
Scientific Publications | 6 Jun 2022

ASCO2022: Surufatinib in US Patients with Soft Tissue Sarcoma
Surufatinib in U.S. patients with soft tissue sarcoma   Authors Sujana Movva, Alexander I. Spira, Erika P. Hamilton, Judy S. Wang, Allen Lee Cohn, James F. Strauss, Silvia Stacchiotti, Chris Tucci, John Kauh, Shivani Nanda, Marek K. Kania, Sh
Read More
Scientific Publications | 6 Jun 2022

ASCO2022: A pooled analysis of surufatinib safety from phase 3 trials in advanced NETs
A pooled analysis of surufatinib safety from phase 3 trials in advanced NETs   Authors Jie Li, Jianming Xu, Lin Shen, Chunmei Bai, Zhiwei Zhou, Zhiping Li, Yihebali Chi, Xianjun Yu, Enxiao LI, Nong Xu, Tianshu Liu, Wenhui Lou, Yuxian Bai, Xia
Read More
Scientific Publications | 12 Dec 2021

ASH 2021: Preliminary Results from a Phase I Study of HMPL-523, a Selective, Oral Syk Inhibitor, in Patients with Relapsed or Refractory Lymphoma.
View Poster (PDF)
Scientific Publications | 3 Nov 2021

NANETS 2021: Interim Analysis Results of Surufatinib in US Patients with Neuroendocrine Tumors
View Poster (PDF)
Scientific Publications | 17 Sep 2021

ESMO2021: A Phase Ib/II Study of Fruquintinib in Combination with Tislelizumab in Patients with Advanced Triple Negative Breast Cancer
Title: An open-label, phase Ib/II study to evaluate the safety and efficacy of fruquintinib in combination with tislelizumab in patients with advanced triple negative breast cancer Lead Author: Debu Tripathy, MD, The University of Texas
Read More
View Poster (PDF)
Presentations, Scientific Publications | 22 Jun 2021

The Lancet Respiratory Medicine: Savolitinib in Chinese NSCLC patients harbouring MET exon 14 skipping alterations
Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study   Shun Lu, Jian Fang
Read More
Scientific Publications | 4 Jun 2021

ASCO 2021: An Open-Label Phase 1b/2 Study of Surufatinib in Combination with Tislelizumab  in Patients with Advanced Solid Tumors
View Poster (PDF)
Scientific Publications | 4 Jun 2021

ASCO 2021: Interim Analysis Results of Surufatinib in US Patients with Neuroendocrine Tumors (NETs)
View Poster (PDF)
Scientific Publications | 4 Jun 2021

ASCO 2021: A Multicenter Open-Label Phase 1 Study Evaluating the Safety and Tolerability of HMPL-306 in Patients with Locally Advanced or Metastatic Solid Tumors with IDH Mutations
View Poster (PDF)
Scientific Publications | 9 Apr 2021

AACR 2021: ctDNA Analysis in the Savolitinib Phase II Study in NSCLC Patients Harboring METex14 Skipping Alterations
Presenter/Authors: Yongfeng Yu, Yongxin Ren, Jian Fang, Lejie Cao, Zongan Liang, Qisen Guo, Sen Han, Zimei Ji, Ye Wang, Yulan Sun, Yuan Chen, Xingya Li, Hua Xu, Jianying Zhou, Liyan Jiang, Ying Cheng, Zhigang Han, Jianhua Shi, Gongy
Read More
View Poster (PDF)
Presentations, Scientific Publications | 15 Jan 2021

ASCO-GI 2021: FRESCO-2 global Phase III study of fruquintinib in mCRC
FRESCO-2: A global phase 3 study of the efficacy and safety of fruquintinib in patients (pts) with metastatic colorectal cancer (mCRC) Arvind Dasari, James Yao, Alberto Sobrero, Takayuki Yoshino, William Schelman, Shivani Nanda, Caly Chien, Su-Fen
Read More
View Poster (PDF)
Presentations, Scientific Publications | 5 Dec 2020

ASH2020: Results from a Phase 1 Dose Escalation Study of HMPL-689, a Selective Oral PI3Kδ Inhibitor, in Chinese Patients with Relapsed/Refractory Lymphomas
Title: Results from a Phase 1 Dose Escalation Study of HMPL-689, a Selective Oral Phosphoinositide 3-Kinase-Delta Inhibitor, in Chinese Patients with Relapsed/Refractory (R/R) Lymphoma Lead Author: Junning Cao, Zhiming Li, MD PhD, Jianfen
Read More
View Abstract (PDF)Download Presentation (PDF)
Presentations, Scientific Publications | 21 Sep 2020

The Lancet Oncology: Surufatinib SANET-p phase 3 study
Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study Jianming Xu*, Lin Shen*, Chunmei Bai*, Wei Wang*, Jie Li, Xianjun Yu, Zhiping Li, Enxiao Li, Xianglin Yuan, Yihe
Read More
Presentations, Scientific Publications | 21 Sep 2020

The Lancet Oncology: Surufatinib SANET-ep phase 3 study
Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study Jianming Xu*, Lin Shen*, Zhiwei Zhou, Jie Li, Chunmei Bai, Yihebali Chi, Zhiping Li, Nong Xu, Enxiao Li, T
Read More
Presentations, Scientific Publications | 20 Sep 2020

ESMO2020: Surufatinib for patients with advanced pancreatic NET (SANET-p)
Title: Surufatinib (S) for patients (Pts) with advanced pancreatic neuroendocrine tumors (SANET-p): a randomized, double-blind, placebo (P)-controlled Phase III trial (NCT02589821) Lead Author: Jianming Xu, Head of the Department of Gast
Read More
Download Presentation (PDF)
Presentations, Scientific Publications | 18 Sep 2020

ESMO2020: Phase1/1b Trial of Fruquintinib in Patients with Advanced Solid Tumors
Title: Phase (Ph) 1/1b Trial of Fruquintinib (Fru) in Patients (Pts) with Advanced Solid Tumors: Preliminary Results of the Dose Expansion (Exp) Cohort in Refractory Metastatic Colorectal Cancer (mCRC) Lead Author: N. Arvind Dasari, Asso
Read More
View Poster (PDF)
Presentations, Scientific Publications | 18 Sep 2020

ESMO2020: SANET-ep study subgroup analysis by Ki-67 and primary tumor origins
Title: Subgroup analysis by Ki-67 and primary tumor origins of the randomized, placebo-controlled phase 3 study of surufatinib in advanced well-differentiated extrapancreatic neuroendocrine tumors (SANET-ep) Lead Author: Zhiwei Zhou, Dir
Read More
View Poster (PDF)
Presentations, Scientific Publications | 27 Apr 2020

AACR2020: Comparison of Pharmacokinetic Profiles and Safety of Surufatinib in Patients from China and the United States
Title: Comparison of Pharmacokinetic Profiles and Safety of Surufatinib in Patients from China and the United States Presenter: Arvind Dasari Authors: A Dasari1, S Paulson2, E Hamilton3, J Wang4, M Sung5, G Falchook6, C Tucci7, K
Read More
Download Presentation (PDF)
Presentations, Scientific Publications | 27 Apr 2020

AACR2020: A Phase I Trial of Surufatinib plus Toripalimab in Patients with Advanced Solid Tumor
Title: A Phase I Trial of Surufatinib Plus Toripalimab in Patients with Advanced Solid Tumors Presenter: Yanshuo Cao Authors: M Lu1, Y Cao1, J Gong1, Y Sun2, J Li1, L Shen1. 1 Department of Gastrointestinal Oncology, Key Labor
Read More
Download Presentation (PDF)
Presentations, Scientific Publications | 13 Mar 2020

ENETS 2020 : Safety Profile and AESI for Surufatinib in Chinese Patients with Advanced Extra-Pancreatic Neuroendocrine Tumors: Analysis of the Phase 3 SANET-ep Trial
The previously reported SANET-ep trial (clinicaltrials.gov identifier NCT02588170) demonstrated that surufatinib significantly improves progression-free survival (“PFS”) in patients with advanced extrapancreatic (non-pancreatic) neuroendocrine tu
Read More
View Poster
Presentations, Scientific Publications | 6 Feb 2020

The Lancet Oncology: Osimertinib plus Savolitinib in EGFRm+, MET+ NSCLC
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study Lecia V Sequist;
Read More
Presentations, Scientific Publications | 29 Sep 2019

ESMO 2019: Efficacy and Safety of Surufatinib in Patients with Well-Differentiated Advanced Extrapancreatic NETs
Title:   Efficacy and Safety of Surufatinib in Patients with Well-Differentiated Advanced Extrapancreatic Neuroendocrine Tumors: Results from the Randomized Phase III Study (SANET-ep) Presenting Author: Jianming Xu, Head of th
Read More
Download Presentation (PDF)
Presentations, Scientific Publications | 21 Sep 2019

CSCO 2019: Association Between Hand-Foot Skin Reaction (HFSR) and Survival Benefit of Fruquintinib in FRESCO Trial
Presentation Title : Association Between Hand-Foot Skin Reaction and Survival Benefit of Fruquintinib in FRESCO Trial Presenting Author: Yuxian Bai, Harbin Medical University Cancer Hospital Other Authors: Jin Li, Shukui Qin, Yanho
Read More
Download Presentation (PDF)
Presentations, Scientific Publications | 19 Sep 2019

CSCO 2019 : Subgroup Analysis of Patients With Metastatic Colorectal Cancer Treated With Fruquintinib in the FRESCO Trial Who Had Liver Metastasis
Presentation Title : Subgroup Analysis of Patients With Metastatic Colorectal Cancer Treated With Fruquintinib in the FRESCO Trial Who Had Liver Metastasis Presenting Author: Shukui Qin, Nanjing Chinese Medicine University Affiliated Bay
Read More
Download Presentation (PDF)
Presentations, Scientific Publications | 9 Sep 2019

WCLC 2019: Phase III Fruquintinib v.s. Placebo in Advanced Non-Small Cell Lung Cancer (FALUCA)
MA14.05 - A Randomized Phase III Trial of Fruquintinib Versus Placebo in Patients with Advanced Non-Small Cell Lung Cancer (FALUCA)   Venue: IASLC 2019 World Conference on Lung Cancer in Barcelona, Spain Session:MA14 - The Adequate MTarget
Read More
Download Presentation (PDF)
Presentations, Scientific Publications | 1 Jun 2019

Clin Cancer Res: Surufatinib in advanced, well-differentiated neuroendocrine tumors
Surufatinib in advanced well-differentiated neuroendocrine tumors: a multicenter, 3 single-arm, open-label, phase Ib/II trial Jianming Xu, Jie Li, Chunmei Bai, Nong Xu, Zhiwei Zhou, Zhiping Li, Caicun Zhou, Ru Jia, Ming Lu, Yuejuan Cheng, Chenyu Mao
Read More
Presentations, Scientific Publications | 26 Jun 2018

JAMA: Fruquintinib vs Placebo in Previously Treated Metastatic Colorectal Cancer
Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer The FRESCO Randomized Clinical Trial Jin Li; Shukui Qin; Rui-Hua Xu; Lin Shen; Jianming Xu; Yuxian Bai; Lei Yang; Yanhong Deng;
Read More
Presentations, Scientific Publications | 4 Jun 2018

ASCO 2018: Colorectal cancer Q-TWiST with fruquintinib treatment in FRESCO
Quality-adjusted time without symptoms or toxicity (Q-TWiST) of patients with metastatic colorectal cancer treated with fruquintinib in FRESCO Presenter: Yu-Xian Bai Other Authors: Hongyan Li, Ning Wang, Xiaojun Guo, Wei Wang, Songhua F
Read More
View Poster
Presentations, Scientific Publications | 4 Jun 2018

ASCO 2018: Subgroup analysis by prior anti-VEGF or anti-EGFR target therapy in FRESCO
Presenter:     Ruihua Xu Other Authors: Jin Li, Yu-Xian Bai, Yanhong Deng, Lei Yang, Haijun Zhong, Zhendong Chen, Hongming Pan, Weijian Guo, Yongqian Shu, Ying Yuan, Jianming Xu, Lin Shen, Ning Wang, Xin Wang, Haidong Chi, Jack Peng, Y
Read More
Presentations, Scientific Publications | 17 Apr 2018

AACR 2018: MET gene copy number gains evaluated by NGS is more predictive than other methods to enrich for papillary RCC patients sensitive to savolitinib
4541 / 26 - MET gene copy number gains evaluated by NGS is more predictive than other methods to enrich for papillary RCC patients sensitive to savolitinib, a selective MET inhibitor Presenter/Authors M. M. Frigault1, S. Signoretti2, A. Markovets
Read More
View Poster
Presentations, Scientific Publications | 23 Mar 2018

ASCPT 2018: Fruquintinib Pharmacokinetics in Humans
Pharmacokinetics of Fruquintinib in Humans Venue: American Society for Clinical Pharmacology & Therapeutics Annual Meeting in Orlando, Florida, USA Abstract #: PII-116 Authors: Ke Li, Chen Yu, Yanmei Liu, Xiangkun Li, Sumei Xia, Jian Wa
Read More
Download Poster Presentation (PDF)
Presentations, Scientific Publications | 12 Mar 2018

Journal of Clinical Oncology: Phase II Trial of Fruquintinib in Patients with Advanced Nonsquamous NSCLC
 Shun Lu, Jianhua Chang, Xiaoqing Liu, Jianhua Shi, You Lu, Wei Li, Jin-ji Yang, Jianying Zhou, Jie Wang, Tongtong An, Lei Yang, Zhe Liu, Xiangdong Zhou, Mo Chen, Ye Hua and Weiguo Su Abstract Purpose Patients with advanced non‒small-cell lung
Read More
Presentations, Scientific Publications | 24 Feb 2018

ACOS 2018: Adverse Events of Special Interest Profiles and Time Courses of Fruquintinib in the FRESCO Trial
Venue: The 13th International Conference of the Asian Clinical Oncology Society in Chiang Mai, Thailand Abstract #: ABS093 Authors: Jin Li, Shukui Qin, Yuxian Bai, Yanhong Deng, Lei Yang, Zhendong Chen, Haijun Zhong, Rui-hua Xu, Hongming Pan,
Read More
Download Slides (PDF)
Presentations, Scientific Publications | 20 Feb 2018

ICTO2018: Phase Ib of Savolitinib and Durvalumab in Renal Cell Carcinoma (CALYPSO)
A Phase Ib Study of Durvalumab (MEDI4736) in Combination with Savolitinib in Patients with Metastatic Renal Cell Carcinoma S Vari1, B Szabados1, A GomezdeLiano1, K Mousa2, L Rammazzo2, A Prendergast2, T Powles1 1 Barts Health NHS Trust, Barts Can
Read More
Presentations, Scientific Publications | 17 Oct 2017

WCLC 2017: Phase Ib/II savolitinib plus Iressa® in MET-driven NSCLC
OA 09.06 – A Phase Ib Trial of Savolitinib plus Gefitinib for Chinese Patients with EGFR-Mutant MET-Amplified Advanced NSCLC Jin-Ji Yang, Jian Fang, Y. Shu, J. Chang, G. Chen, J. He, W. Li, X. Liu, N. Yang, Caicun Zhou, J. Huang, L. Yang, A.A. Han
Read More
Presentations, Scientific Publications | 17 Oct 2017

WCLC 2017: Phase Ib/II savolitinib plus Tagrisso® in MET-driven NSCLC
OA 09.03 – TATTON Ph Ib Expansion Cohort: Osimertinib plus Savolitinib for Pts with EGFR-Mutant MET-Amplified NSCLC after Progression on Prior EGFR-TKI Myung-Ju Ahn, Ji-Youn Han, Lecia V Sequist, Byoung Chul Cho, J.S. Lee, Sang-We Kim, W. Su, C. T
Read More
Presentations, Scientific Publications | 15 Oct 2017

WCLC 2017: Phase II fruquintinib combination with Iressa in NSCLC
JCSE 01.12 – A Phase II study of fruquintinib in combination with gefitinib in stage IIIb/IV NSCLC patients harboring EGFR activating mutations (NCT02976116) Shun Lu, Jianying Zhou, Xiaomin Niu, Mo Chen, Hongyan Yin, Ye Hua, Weiguo Su Venue: IA
Read More
Presentations, Scientific Publications | 28 Sep 2017

CSCO 2017: Savolitinib Phase Ib in c-MET Gastric Cancer
Phase Ib Trial of the Safety and Antitumor Activity of Savolitinib in Advanced Gastric Cancer Patients with Aberrant c-MET Jifeng Feng, Baorui Liu, Tianshu Liu, Nong Xu, Jianming Xu, Yunpeng Liu, Yuxian Bai, Jin Li, Wei Li, Chunmei Bai, Tao Zhang,
Read More
Download Slides (PDF)
Presentations, Scientific Publications | 28 Sep 2017

CSCO 2017: Theliatinib Phase I Results
Novel EGFR TKI Theliatinib: An Open Label, Dose Escalation Phase I Clinical Trial Lin Shen, Li Zhang, Hongyun Zhao, Wenfeng Fang, Jifang Gong Venue: Chinese Society of Clinical Oncology Annual Meeting Session: Esophageal Cancer Presenter: Jif
Read More
Download Slides (PDF)
Presentations, Scientific Publications | 27 Sep 2017

CSCO 2017: FRESCO In-Depth Analysis
In-depth Analysis of the FRESCO Study: a Randomized, Double-blind, Phase III Trial Evaluating the Efficacy and Safety of Fruquintinib in Patients with 3+ Line Advanced Colorectal Cancer Shukui QIN*, Jin LI*, Yuxian BAI, Yanhong DENG, Lei YANG, Zhen
Read More
Download Slides (PDF)
Presentations, Scientific Publications | 27 Sep 2017

CSCO 2017: Theliatinib Preclinical Study in Esophageal Cancer
Is EGFR a “feasible” target for advanced esophageal cancer treatment? Rongxin Ren, Shiming Fan, Linfang Wang,Min Cheng, Dongxia Shi,  Wei Zhang,Renxiang Tang, Ying Yu, Longxian Jiao, Jun Ni, Haibin Yang, Huaqing Cai,Feng Zhou, Weihan Zhang, Wei
Read More
Presentations, Scientific Publications | 23 Jun 2017

Journal of Clinical Oncology: Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced PRCC
Toni K. Choueiri, Elizabeth Plimack, Hendrik-Tobias Arkenau, Eric Jonasch, Daniel Y.C. Heng, Thomas Powles, Melanie M. Frigault, Edwin A. Clark, Amir A. Handzel, Humphrey Gardner, Shethah Morgan, Laurence Albiges, and Sumanta Kumar Pal Abstract Pur
Read More
Presentations, Scientific Publications | 5 Jun 2017

ASCO 2017: Fruquintinib Phase III in Metastatic Colorectal Cancer (FRESCO)
A randomized, double-blind, placebo-controlled, multi-centered phase III trial comparing fruquintinib versus placebo plus best supportive care in Chinese patients with metastatic colorectal cancer (FRESCO) Venue: American Society of Clinical Oncol
Read More
View Presentation Slides (PDF)
Presentations, Scientific Publications | 5 Jun 2017

ASCO 2017: Sulfatinib Phase II in Medullary and Differentiated Thyroid Cancer
A phase II multicenter trial of the multitargeted kinase inhibitor sulfatinib in advanced medullary thyroid cancer (MTC) and radioiodine (RAI)-refractory differentiated thyroid cancer (DTC) Venue: American Society of Clinical Oncology Annual Meeti
Read More
Download Poster Presentation (PDF)
Presentations, Scientific Publications | 4 Apr 2017

AACR 2017: Preclinical evaluation of sulfatinib, a novel angio-immuno kinase inhibitor targeting VEGFR, FGFR1 and CSF-1R kinases
Preclinical evaluation of sulfatinib, a novel angio-immuno kinase inhibitor targeting VEGFR, FGFR1 and CSF-1R kinases Authors: Jinghong Zhou, Jun Ni, Min Cheng, Na Yang, Junqing Liang, Liang Ge, Wei Zhang, Jianxing Tang, Qiaoling Sun, Fu Li, Jia Hu,
Read More
Download Presentation (PDF)
Presentations, Scientific Publications | 3 Apr 2017

AACR 2017: Fruquintinib combinations with targeted therapies or immune checkpoint inhibitors in preclinical tumor models
Evaluation of fruquintinib, a potent and selective oral VEGFR inhibitor, in combination with targeted therapies or immune checkpoint inhibitors in preclinical tumor models Authors: Yongxin Ren, Qiaoling Sun, Jingwen Long, Shiming Fan, Renxiang Tang,
Read More
Download Presentation (PDF)
Presentations, Scientific Publications | 9 Mar 2017

ENETS 2017: Sulfatinib Phase Ib/II in Advanced Neuroendocrine Tumors
An Open-Label Phase Ib/II Study of Sulfatinib in Patients with Advanced Neuroendocrine Tumors (NCT02267967) Authors: J.M. Xu, J. Li, C.M. Bai, N. Xu, Z.W. Zhou, Z.P. Li, C.C. Zhou, W. Wang, J. Li, C. Qi, Y. Hua, W.G. Su Summary: The current Phase
Read More
Download Presentation (PDF)
1
2